Kalcipos-D forte 500 mg/ 800 IU film-coated tablets
- Name:
Kalcipos-D forte 500 mg/ 800 IU film-coated tablets
- Company:
Mylan IRE Healthcare Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/04/20
(Click to Download)Click on this link to Download PDF directly
Mylan IRE Healthcare Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 12 April 2020 PIL
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 17 January 2020 PIL
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 22 August 2019 PIL
Reasons for updating
- Change to name of medicinal product
Updated on 8 November 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 7 November 2018 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 16 July 2018 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 4.4: Information regarding milk-alkali syndrome added
In section 4.6: Information regarding pregnancy added
In section 4.8: Full adverse reaction definitions added
In section 5.1: Information regarding pharmacotherapeutic group added
In section 5.2: Information regarding absorption, distribution added
In section 10: Date of revision changed.
Updated on 27 July 2017 SmPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 4.1: Information regarding indication for adults and children over 18 years has been added
In section 5.2: Pharmacokinetic properties information has been added
In section 10: Date of revision changed.
Updated on 27 July 2017 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 27 July 2017 PIL
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 4.1: Information regarding indication for adults and children over 18 years has been added
In section 5.2: Pharmacokinetic properties information has been added
In section 10: Date of revision changed.
Updated on 12 January 2016 PIL
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 2: there is a slight text change
In section 4,2: Restructuring to this section has been undertaken
In section 4.3: Slight amendment to information added
In section 4.5: Information regarding calcium salts has been added. Information regarding orlistat has been added.
In section 4.7: Warning in relation to driving and use of machinery has been added
In section 4.8: Information regarding patients with renal impairment has been added
In section 5.2: Minor text added
In In section 10: The date of revision has been changed.
Updated on 12 January 2016 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 2: there is a slight text change
In section 4,2: Restructuring to this section has been undertaken
In section 4.3: Slight amendment to information added
In section 4.5: Information regarding calcium salts has been added. Information regarding orlistat has been added.
In section 4.7: Warning in relation to driving and use of machinery has been added
In section 4.8: Information regarding patients with renal impairment has been added
In section 5.2: Minor text added
In In section 10: The date of revision has been changed.
Updated on 10 October 2013 SmPC
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 5.1: Additional information has been added to this section outlining the results of a clinical study
In section 10: The date of revision has been changed.
Updated on 10 October 2013 PIL
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 5.1: Additional information has been added to this section outlining the results of a clinical study
In section 10: The date of revision has been changed.
Updated on 30 November 2012 PIL
Reasons for updating
- New SPC for new product
Free text change information supplied by the pharmaceutical company
Updated on 30 November 2012 SmPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)